Table 4.
Management profile of study subjects.
|
Medications Received before presenting to ER |
≤35years (102) n (%) |
>35 years (104) n (%) |
|
| None | 27 (26.5%) | 32 (30.8%) | |
| Aspirin ± Statin | 14 (13.7%) | 21 (20.2%) | |
| Aspirin + Clopidogrel | 10 (9.8%) | 17 (16.3%) | |
| Aspirin + Clopidogrel + Statin | 45 (44.1%) | 26 (25%) | |
| Aspirin + Clopidogrel + Statin + Antithrombotics |
6 (5.9%) |
8 (7.7%) |
|
| The p-value is .06. | |||
|
Mode of Treatment At ER for STEMI patients |
≤ 35years (93) n (%) |
>35 years (95) n (%) |
|
| Thrombolysis | 30 (32.3%) | 24 (25.3%) | |
| Agent used for thrombolysis | STK | 21 (70%) | 12 (50%) |
| RTP | 4 (13.3%) | 8 (33.3%) | |
| TNK | 5 (16.7%) | 4 (16.7%) | |
| Primary PCI | 34 (36.6%) | 25 (26.3%) | |
| Conservative Management | 29 (31.2%) | 46 (48.4%) | |
| Reason for Conservative management | Not mentioned | 14 (48.3%) | 20 (43.5%) |
| Resolution of symptoms | 5 (17.2%) | 7 (15.2%) | |
| Not willing for admission | 4 (13.8%) | 4 (8.7%) | |
| OWP |
6 (20.7%) |
15 (32.6%) |
|
| The p-value is .05307. | |||
|
Medications received before discharge from hospital |
≤ 35years (102) n (%) |
>35 years (104) n (%) |
|
| Aspirin | 102 (100%) | 104 (100%) | |
| Thienopyridines | Clopidogrel | 97 (95.1%) | 104 (100%) |
| Prasugrel | 6 (5.9%) | 0 | |
| Statin | 102 (100%) | 104 (100%) | |
| ACEIs | 90 (88.2%) | 96 (92.3%) | |
| Β-blockers | 92 (90.2%) | 93 (89.4%) | |
| Anticoagulants | UFH | 4 (3.9%) | 13 (12.5%) |
| LMWH | 87 (85.3%) | 87 (83.6) | |
STEMI, ST segment elevation myocardial infarction; PCI, percutaneous coronary intervention; TNK, tenecteplase; RTP, reteplase.